(ICU) SeaStar Medical Holding Corporation Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ICU) SeaStar Medical Holding Corporation Complete Analysis Pack
Actionable Strategy Starts Here
This SeaStar Medical Holding Corporation 4P's Marketing Mix Analysis explains the company’s product offerings, pricing approach, distribution channels, and promotional tactics in a concise, actionable format. The page shows a genuine preview/sample of the analysis so you can evaluate style and content; purchase the full version to receive the complete ready-to-use report.
Product
QUELIMMUNE HDE
QUELIMMUNE HDE is SeaStar Medical Holding Corporation’s lead commercial product and first FDA-authorized marketed therapy, aimed at pediatric acute kidney injury with sepsis that needs continuous renal replacement therapy. In the 4P mix, this is the core Product because it targets a high-risk hospital use case with a narrow, specialist-driven label. Its HDE status matters, since Humanitarian Device Exemption products are cleared for rare conditions and help shape pricing, access, and adoption.
Selective Cytopheretic Device platform
SeaStar Medical Holding Corporation’s Selective Cytopheretic Device platform is an extracorporeal immune-modulation system that binds and regulates activated effector cells in the blood circuit. Its aim is to calm hyperinflammation and blunt cytokine storm, a pathway tied to acute organ injury and high-care ICU use. The product’s value sits in turning a drug-free blood-treatment platform into a targeted inflammatory control tool.
Blood-contacting therapy
SeaStar Medical Holding Corporation's blood-contacting therapy is a hospital-only device used with dialysis-type critical care support, so each use is tied to an ICU or inpatient procedure, not a retail sale. Because it works outside the body through the extracorporeal circuit, it fits the market as a procedure-linked product with trained staff and repeated device use. The U.S. dialysis population is over 550,000, which shows the scale of the care setting this product serves.
Adult AKI pipeline
SeaStar Medical Holding Corporation is advancing its adult AKI pipeline for critically ill patients on CRRT, expanding the platform beyond pediatrics. This target is attractive because severe AKI is common in ICUs, and CRRT is often used when kidney failure is life-threatening. The adult program could widen the addressable market well beyond the pediatric niche.
- Adult ICU patients on CRRT
- Expansion beyond pediatrics
- Higher market reach potential
Broad critical care pipeline
SeaStar Medical Holding Corporation broad critical care pipeline extends its inflammation-control approach into cardiorenal syndrome in congestive heart failure, including patients with and without LVADs, plus myocardial stunning in end-stage renal disease and hepatorenal syndrome. Acute kidney injury can affect up to 50% of ICU patients, so even small gains can matter.
- Targets multiple ICU syndromes
- Uses one inflammation-control concept
- Fits high-need, high-risk care
SeaStar’s QUELIMMUNE Targets a High-Need ICU Kidney Crisis
SeaStar Medical Holding Corporation’s Product is QUELIMMUNE HDE, a first FDA-authorized, hospital-only immune-modulation device for pediatric sepsis-associated acute kidney injury on CRRT. Its Humanitarian Device Exemption fits a rare, high-acuity use case and supports specialist adoption.
The platform also aims at adult AKI and other ICU syndromes, widening use beyond pediatrics. With acute kidney injury affecting up to 50% of ICU patients, the addressable need is large.
| Product | Use | Stage | Need |
|---|---|---|---|
| QUELIMMUNE HDE | Pediatric AKI on CRRT | FDA-authorized | High-acuity ICU |
What is included in the product
Detailed Word Document
A concise, company-specific breakdown of SeaStar Medical Holding Corporation’s 4P marketing mix, grounded in real market positioning and strategic context.
Editable Excel File
Clarifies SeaStar Medical’s 4Ps to quickly ease strategic confusion and support faster marketing decisions.
Reference Sources
Consolidates primary industry reports, regulatory filings, and benchmark datasets to speed due diligence and verify SeaStar Medical market, pricing, and unit-economics claims.
Place
Denver, Colorado headquarters
SeaStar Medical Holding Corporation is headquartered in Denver, Colorado, where corporate, regulatory, and commercialization work is managed from one U.S. base. The Denver site helps coordinate distribution and partner activity across 3 core functions: governance, compliance, and market rollout. That central setup supports faster execution in the U.S. medtech market, where regulated launch timing can shape revenue.
U.S. hospital market
SeaStar Medical Holding Corporation targets the U.S. hospital market because QUELIMMUNE is used in ICU and other institutional critical care settings, not retail channels. The U.S. has about 6,100 hospitals and roughly 920,000 staffed beds, so distribution depends on hospital procurement, clinical adoption, and direct deployment inside care teams.
Pediatric ICU access
Pediatric ICU access is narrow and clinical: SeaStar Medical Holding Corporation’s lead use is for pediatric acute kidney injury in critically ill children, so adoption starts in pediatric intensive care units that already run CRRT programs. AKI affects about 30% to 50% of critically ill children, but only a limited set of hospitals have the staff and machines to deliver renal replacement therapy. That makes site selection and CRRT footprint the key gate.
CRRT-capable centers
SeaStar Medical Holding Corporation’s therapy is placed in CRRT-capable centers because it must run through continuous renal replacement therapy in the ICU. That puts the buyer set in nephrology and critical care units that already have dialysis machines, trained staff, and extracorporeal blood-flow protocols.
- ICU CRRT sites are the key channel
- Dialysis-ready units are the target
- Placement follows existing workflows
Academic and referral hospitals
Academic and referral hospitals are SeaStar Medical Holding Corporation's core place channel, because the sickest ICU patients are concentrated in tertiary and quaternary centers and are most likely to get a novel device evaluation. In 2025, this means specialist-led adoption, not broad outpatient reach, which fits a high-acuity model with long clinical review cycles.
- Best fit: tertiary and quaternary ICUs
- Targets the sickest, highest-need patients
- Supports specialist-driven device use
- Limits need for wide outpatient distribution
U.S.-Centered Hospital Strategy Drives QUELIMMUNE Adoption
SeaStar Medical Holding Corporation’s place strategy is U.S.-centered, with Denver used to manage regulation, partners, and launch work. QUELIMMUNE is placed in ICU and CRRT-capable hospitals, so adoption depends on nephrology and critical care teams, not retail channels. The core market is tertiary and quaternary children’s hospitals, where severe AKI cases concentrate.
| Place factor | Key data |
|---|---|
| HQ | Denver, Colorado |
| U.S. hospitals | About 6,100 |
| Staffed beds | About 920,000 |
| Channel | ICU CRRT sites |
Full Version Awaits
SeaStar Medical Holding Corporation Reference Sources
The preview shown here is the actual SeaStar Medical Holding Corporation 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises; it’s the full, ready-to-use document covering Product, Price, Place, and Promotion with actionable insights.
Promotion
FDA HDE milestone
FDA Humanitarian Device Exemption is a strong promo asset for SeaStar Medical Holding Corporation because it gives QUELIMMUNE a formal regulatory stamp in a rare-use setting. The HDE route is limited to diseases affecting fewer than 8,000 U.S. patients a year, so it signals clinical need and helps hospitals trust the product in acute kidney injury linked to sepsis. That FDA status also sets QUELIMMUNE apart in a narrow pediatric market for patients weighing 10 to less than 50 kg.
Clinical data dissemination
SeaStar Medical Holding Corporation’s promotion leans on clinical data, not broad ads, because physicians and hospitals buy on proof. The company uses study results, safety data, and peer-reviewed or conference-presented findings to show how its device performs in real care. That fits a market where the first FDA-authorized QUELIMMUNE therapy for pediatric acute kidney injury came in 2024, so evidence drives adoption.
Medical congress presence
SeaStar Medical Holding Corporation uses medical congress presence in nephrology, critical care, and pediatrics to reach the specialists who manage CRRT and AKI, where more than 2 million AKI hospital cases occur each year in the U.S. alone. These forums support physician education, build clinical trust, and create direct lead flow for adoption discussions.
Key opinion leader outreach
SeaStar Medical Holding Corporation’s audience is clinician-led, so key opinion leader outreach is central: it helps doctors explain the device’s mechanism and patient-selection criteria in ICU settings, where the therapy is novel and high-stakes. In 2025, the company still needed trusted clinical voices to support adoption of QUELIMMUNE after its FDA Humanitarian Device Exemption, because bedside use depends on clear case selection and workflow fit. That makes KOL education a direct driver of awareness, confidence, and trial use.
Clinician trust drives ICU adoption.
KOLs clarify mechanism and selection.
Novel therapies need bedside proof.
Investor and corporate communications
SeaStar Medical Holding Corporation uses press releases, SEC filings, and earnings materials to promote its investor and corporate story. These updates track QUELIMMUNE commercialization, milestones, and pipeline steps, helping both healthcare buyers and investors follow progress after its 2023 FDA De Novo authorization for the first marketed product.
- Tracks commercialization progress
- Shares SEC and earnings updates
- Supports investor and clinician awareness
SeaStar Builds ICU Trust with KOLs, Congresses, and FDA Proof
SeaStar Medical Holding Corporation’s promotion is specialist-led and proof-based: QUELIMMUNE’s FDA Humanitarian Device Exemption and 2024 first authorization help build trust with ICU and nephrology buyers. The company leans on congresses, KOLs, and clinical data to reach the more than 2 million U.S. AKI hospital cases each year.
| Channel | Role | Data point |
|---|---|---|
| KOLs | Clinical trust | ICU adoption |
| Congresses | Physician education | AKI and CRRT |
| FDA HDE | Regulatory proof | Rare use under 8,000 patients |
Price
No public list price
SeaStar Medical Holding Corporation has not published a standard list price for QUELIMMUNE, which fits a hospital-only device sold through negotiated contracts, not shelf pricing. The company’s model is aimed at inpatient use in critically ill pediatric patients, so pricing is usually set case by case with hospitals and payers rather than posted publicly.
Institutional contracting
SeaStar Medical Holding Corporation sells into hospitals and health systems, so pricing is usually negotiated by account or facility, not set at a single list price. In this model, each order depends on clinical use, formulary approval, and procurement sign-off, which can lengthen sales cycles but support stickier contracts. For a device sold into acute care, that means access and reimbursement decisions matter as much as the product itself.
Procedure-linked economics
SeaStar Medical Holding Corporation’s QUELIMMUNE is used in a CRRT setting, so the price is tied to a hospital procedure episode and folded into the ICU budget, not sold as a consumer cash price. That means buying is judged against the full critical-care case, where one ICU day can cost thousands of dollars and CRRT is billed as part of the stay.
Reimbursement-dependent adoption
SeaStar Medical Holding Corporation’s pricing has to fit hospital reimbursement, not just device value. In critical care, a product can stall if the hospital cannot code and bill it cleanly, even when clinical need is clear. CMS’s 2025 inpatient hospital payment update was 2.9%, so any new device must protect already thin margins.
- Reimbursement drives ICU adoption.
- Billing codes shape hospital margins.
- Price must fit payment pathways.
Single-patient therapy model
SeaStar Medical Holding Corporation uses a single-patient therapy model, so pricing fits per-treatment or per-patient economics, not a subscription. That matches acute ICU use, where one severe episode can cost tens of thousands of dollars per stay, and the U.S. ICU market still centers on episodic care. For buyers, the value case is tied to reducing high-cost, high-risk ICU events.
- Per-patient pricing fits acute care
- Best for severe ICU episodes
- Value depends on avoided ICU costs
SeaStar’s ICU Pricing Hinges on Hospital Reimbursement
SeaStar Medical Holding Corporation’s price is negotiated hospital by hospital, not posted as a list price, because QUELIMMUNE is sold for ICU and CRRT use. That makes reimbursement and coding central to adoption; CMS’s 2025 inpatient update was 2.9%, so pricing must fit thin hospital margins and per-patient economics.
| Price factor | Key data |
|---|---|
| Pricing model | Negotiated, not public |
| Use setting | Hospital ICU / CRRT |
| Reimbursement pressure | CMS 2025 IPPS +2.9% |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.